Sheeba K Thomas

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study
    M Kay Garcia
    Department of Lymphoma Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0429, Houston, Texas 77030, USA
    J Hematol Oncol 7:41. 2014
  2. pmc Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma
    Jatin J Shah
    Departments of Lymphoma Myeloma
    Ther Clin Risk Manag 5:151-9. 2009
  3. doi request reprint Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma
    Sheeba K Thomas
    Division of Cancer Medicine, Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 0429, Houston, TX, 77030, USA
    Cancer Chemother Pharmacol 73:35-42. 2014
  4. doi request reprint Lymphoma vaccine therapy: next steps after a positive, controlled phase III clinical trial
    Sheeba K Thomas
    Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 39:253-62. 2012
  5. doi request reprint Novel agents for relapsed and/or refractory multiple myeloma
    Sheeba K Thomas
    Division of Cancer Medicine, Department of Lymphoma Myeloma, University of Texas MD Anderson Cancer Center, Holcombe Boulevard, Unit 429, Houston, TX 77030 4009, USA
    Cancer J 15:485-93. 2009
  6. pmc Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma
    Qaiser Bashir
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Am J Hematol 87:272-6. 2012
  7. pmc Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy
    Elisabeth G Vichaya
    Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer Chemother Pharmacol 71:1531-40. 2013
  8. pmc Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma
    Deborah J Kuhn
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
    Blood 120:3260-70. 2012
  9. doi request reprint Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression
    Xin Cao
    a Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Leuk Lymphoma 57:1104-13. 2016
  10. doi request reprint Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation
    Ryan W Jacobs
    Department of Stem Cell Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX
    Clin Lymphoma Myeloma Leuk 16:36-42. 2016

Collaborators

Detail Information

Publications23

  1. pmc Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study
    M Kay Garcia
    Department of Lymphoma Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0429, Houston, Texas 77030, USA
    J Hematol Oncol 7:41. 2014
    ..This single-arm study evaluated feasibility, safety, and initial efficacy of electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy (PN) in cancer patients with multiple myeloma...
  2. pmc Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma
    Jatin J Shah
    Departments of Lymphoma Myeloma
    Ther Clin Risk Manag 5:151-9. 2009
    ..Efforts are now underway to build on this combination further by adding other active anti-myeloma agents. In this review, we will discuss the role of PLD+B as an important addition to our therapeutic armamentarium for patients with MM...
  3. doi request reprint Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma
    Sheeba K Thomas
    Division of Cancer Medicine, Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 0429, Houston, TX, 77030, USA
    Cancer Chemother Pharmacol 73:35-42. 2014
    ..A phase 1 study evaluated the QTc prolongation potential of siltuximab, a chimeric, anti-interleukin-6 mAb, in patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), or low-volume MM...
  4. doi request reprint Lymphoma vaccine therapy: next steps after a positive, controlled phase III clinical trial
    Sheeba K Thomas
    Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 39:253-62. 2012
    ..A first-in-human study is planned to evaluate its use in patients with asymptomatic phase lymphoplasmacytic lymphoma...
  5. doi request reprint Novel agents for relapsed and/or refractory multiple myeloma
    Sheeba K Thomas
    Division of Cancer Medicine, Department of Lymphoma Myeloma, University of Texas MD Anderson Cancer Center, Holcombe Boulevard, Unit 429, Houston, TX 77030 4009, USA
    Cancer J 15:485-93. 2009
    ..In this review, we will discuss the use of these novel agents and their combinations in patients with relapsed and/or refractory multiple myeloma...
  6. pmc Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma
    Qaiser Bashir
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Am J Hematol 87:272-6. 2012
    ..Further studies should be conducted in carefully designed clinical trials in this patient population...
  7. pmc Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy
    Elisabeth G Vichaya
    Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer Chemother Pharmacol 71:1531-40. 2013
    ..g., pain and numbness) in patients with MM undergoing treatment with chemotherapy...
  8. pmc Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma
    Deborah J Kuhn
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
    Blood 120:3260-70. 2012
    ....
  9. doi request reprint Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression
    Xin Cao
    a Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Leuk Lymphoma 57:1104-13. 2016
    ..024), with no difference in progression-free survival and disease-specific survival. Rituximab alone or rituximab-based therapy was used frequently and was effective as either first-line or salvage therapy...
  10. doi request reprint Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation
    Ryan W Jacobs
    Department of Stem Cell Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX
    Clin Lymphoma Myeloma Leuk 16:36-42. 2016
    ..There are limited data on the outcome of NSM after autologous hematopoietic stem cell transplantation (auto-HCT)...
  11. doi request reprint Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma
    Qaiser Bashir
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 53:118-22. 2012
    ..These results indicate that high-dose melphalan plus auto HCT is safe and feasible for patients with multiple myeloma aged ≥70 years and age alone should not be an exclusion criterion for auto HCT...
  12. doi request reprint Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement
    Talha Badar
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Eur J Haematol 97:342-7. 2016
    ..1). In conclusion, median PFS and OS in patients with concurrent cardiac and renal AL were comparable to patients with cardiac AL only, but worse than patients with renal AL. ..
  13. pmc Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia
    Isere Kuiatse
    Department of Lymphoma Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Clin Cancer Res 21:2538-45. 2015
    ..B-cell receptor signaling has been linked to clonal evolution in WMG, and Spleen tyrosine kinase (Syk) is overexpressed in primary cells, suggesting that it could be a novel and rational target...
  14. pmc Subclinical peripheral neuropathy in patients with multiple myeloma before chemotherapy is correlated with decreased fingertip innervation density
    Alyssa K Kosturakis
    Alyssa K Kosturakis, Zijing He, Yan Li, Nina Shah, Sheeba K Thomas, Haijun Zhang, Elisabeth G Vichaya, Xin Shelley Wang, Charles S Cleeland, and Patrick M Dougherty, University of Texas MD Anderson Cancer Center, Houston, TX Jessica A Boyette Davis, York College, York, PA Gwen Wendelschafer Crabb and William R Kennedy, University of Minnesota School of Medicine and Donald A Simone, University of Minnesota School of Dentistry, Minneapolis, MN
    J Clin Oncol 32:3156-62. 2014
    ....
  15. pmc Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma
    Sally A Hunsucker
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    Br J Haematol 152:579-92. 2011
    ..These studies provide a rationale for translation of siltuximab into the clinic in combination with melphalan-based therapies...
  16. ncbi request reprint Lenalidomide in multiple myeloma
    Sheeba K Thomas
    The University of Texas M D Anderson Cancer Center, Department of Lymphoma and Myeloma, 1515 Holcombe Blvd, Box 429, Houston, TX 77030, USA
    Best Pract Res Clin Haematol 20:717-35. 2007
    ..We describe the role of lenalidomide in patients with symptomatic multiple myeloma that is newly diagnosed, relapsed and/or refractory to other therapies, or concurrent with primary amyloidosis...
  17. pmc Validation of the M. D. Anderson Symptom Inventory multiple myeloma module
    Desiree Jones
    Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1450, 77030, Houston, TX 77030, USA
    J Hematol Oncol 6:13. 2013
    ..We sought to validate a module of the M. D. Anderson Symptom Inventory (MDASI) developed specifically for patients with MM (MDASI-MM)...
  18. doi request reprint Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy
    Valerie Reed
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:4468-74. 2011
    ..The objective of this study was to review the outcome of patients with solitary plasmacytoma (SP) after definitive radiation therapy...
  19. doi request reprint Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation
    Fabian Bock
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas Institute of Clinical Chemistry and Pathobiochemistry, Otto von Guericke University, Magdeburg, Germany
    Biol Blood Marrow Transplant 22:2159-2164. 2016
    ..02), respectively. In conclusion, Patients with CKS1B amplification are more likely to have additional high-risk cytogenetic abnormalities and a shorter PFS and OS after an auto-HCT...
  20. pmc Effect of long-term storage in TRIzol on microarray-based gene expression profiling
    Wencai Ma
    The Myeloma Tissue and Leukemia Satellite Sample Banks, Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, Houston, Texas 77054, USA
    Cancer Epidemiol Biomarkers Prev 19:2445-52. 2010
    ....
  21. pmc Changes in pain and other symptoms in patients with painful multiple myeloma-related vertebral fracture treated with kyphoplasty or vertebroplasty
    Tito R Mendoza
    Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Pain 13:564-70. 2012
    ....
  22. pmc Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling
    Xing Ding Zhang
    Department of Lymphoma Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA Cyrus Tang Hematology Center, Soochow University, Suzhou, Jiangsu 215123, China Xi an Jiaotong University Suzhou Academy, Suzhou, Jiangsu 215123, China
    Cancer Cell 29:639-52. 2016
    ....
  23. pmc Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis
    Xin Cao
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
    J Hematol Oncol 8:74. 2015
    ....